论文部分内容阅读
[目的]探讨双歧三联活菌联合水飞蓟宾对非酒精性脂肪肝的疗效。[方法]选取2014年1月~2015年6月我院门诊非酒精性脂肪肝患者120例,随机分为观察组和对照组,观察组予双歧三联活菌散剂联合水飞蓟宾胶囊口服,对照组单独予水飞蓟宾胶囊口服,疗程12周,比较2组肝功能、血脂、肝脏CT评分。[结果]治疗组及对照组各项评分均较治疗前降低,差异有统计学意义(P<0.05);2组比较,治疗组疗效优于对照组(P<0.05)。[结论]双歧三联活菌联合水飞蓟宾胶囊对改善非酒精性脂肪肝患者肝功能、血脂及肝脏CT评分有显著临床疗效。
[Objective] To investigate the efficacy of bifid triple viable silybin in treating non-alcoholic fatty liver disease. [Methods] 120 patients with non-alcoholic fatty liver disease in our hospital from January 2014 to June 2015 were randomly divided into observation group and control group. The observation group received bifidobacterium triple inactivated powder combined with silybin capsule . The control group was orally administered with silybin capsule alone for 12 weeks. The liver function, blood lipid and liver CT score of the two groups were compared. [Results] The scores of the treatment group and the control group were significantly lower than those before treatment (P <0.05). The curative effect of the treatment group was better than that of the control group (P <0.05). [Conclusion] The combination of bifid triple viable sibling with silybin capsule has a significant clinical effect on improving liver function, blood lipid and liver CT score in patients with non-alcoholic fatty liver.